Chardan Capital Markets Downgrades Arrowhead Research (ARWR) to Neutral on EX-1 RNAi Program Discontinuations

November 30, 2016 6:19 AM EST Send to a Friend
Chardan Capital Markets downgraded Arrowhead Research (NASDAQ: ARWR) from Buy to Neutral with a price target of $2.00 (from $8.00) ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login